Abstract:SESSION TITLE: Asthma III SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Asthmatic inflammation is dominated either by eosinophil or neutrophil accumulation in airways. Resolution of these inflammatory cells is the key to disease alleviation. It is well accepted that eosinophilic airway inflammation is responsive to corticosteroid treatment, while neutrophilic inflammation contributes to most of the corticosteroid-insensitive severe asthma and increases the burden of global health care. Here, we explored a new strategy of effective treatment against corticosteroid-insensitive neutrophilic asthma by small molecule inhibitors against anti-apoptotic protein Bcl-2. METHODS: Expression of Bcl-2 on inflammatory cells and inflamed tissues were detected. Resolution of airway inflammation in allergen-challenged Bcl-2 transgenic mice was analyzed. Mouse eosinophils and neutrophils from bronchoalveolar lavage (BAL) fluid in response to ABT-737 was detected by flow cytometry. Eosinophilic and neutrophilic airway inflammation model were treated with ABT-737 or ABT-199, the apoptosis of inflammatory cells and cytokines level were analyzed and airway hyperresponsiveness to aerosolized methacholine was measured. RESULTS: Significantly higher viability and prolonged lifespan of eosinophils and neutrophils were observed in BAL fluid from allergen-induced airway inflammation mouse model showed. This was probably due to elevated expression levels of Bcl-2 protein in these inflammatory cells. It was striking that inflammatory response induced by allergen dramatically aggravated and persisted in vav-Bcl-2 transgenic mice, where nucleated hematopoietic cells were resistant to apoptosis. Based on these above observations, Bcl-2 inhibitors, ABT-737 or ABT-199, were shown to play efficient roles in alleviation of either eosinophilic or neutrophilic allergen-induced airway inflammation. CONCLUSIONS: ABT-737 or ABT-199 may be promising drugs for the treatment against airway inflammation, especially corticosteroid-insensitive neutrophilic airway inflammation. CLINICAL IMPLICATIONS: It is well-accepted that eosinophilic airway inflammation is responsive to corticosteroid treatment, while neutrophilic inflammation contributes to most of the corticosteroid-insensitive severe asthma. We have provided a new strategy to inhibit allergic airway inflammation, especially the neutrophil-dominated and corticosteroid insensitive airway inflammation, by promoting the death of inflammatory cell with the antagonist of anti-apoptotic proteins Bcl-2 termed ABT-737 or ABT-199. DISCLOSURE: The following authors have nothing to disclose: Bao-ping Tian, Li-xia Xia, Zhengqiang Bao, Wen Li, Zhihua Chen, Songmin Ying, Huahao Shen No Product/Research Disclosure Information

The role of JAK/STAT signaling in neutrophilic airway inflammation

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration

Bruton's tyrosine kinase inhibition suppresses neutrophilic inflammation and restores histone deacetylase 2 expression in myeloid and structural cells in a mixed granulocytic mouse model of asthma

The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro

IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD

NF-kappaB Signaling in Chronic Inflammatory Airway Disease

The role of the JAK/STAT signal pathway in rheumatoid arthritis

Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production

IL-1β augments TGF-β inducing epithelial-mesenchymal transition of epithelial cells and associates with poor pulmonary function improvement in neutrophilic asthmatics

Cigarette smoke-induced lung inflammation in COPD mediated via CCR1/JAK/STAT /NF-κB pathway

Induction of Granulocyte Apoptosis by Bcl-2 Inhibitors Reduces Steroid-Insensitive Airway Inflammation

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Pathogenesis of steroid-resistant airway hyperresponsiveness: interaction between IFN-gamma and TLR4/MyD88 pathways

IL-17 Promotes p38 MAPK-Dependent Endothelial Activation Enhancing Neutrophil Recruitment to Sites of Inflammation

Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats

Role of Interleukin-17 and the Neutrophil in Asthma

IL-17A-Induced Redox Imbalance and Inflammatory Responses in Mice Lung via Act1-TRAF6-IKBα Signaling Pathway: Implications for Lung Disease Pathogenesis

In vitro neutrophil migration is associated with inhaled corticosteroid treatment and serum cytokines in pediatric asthma

Bcl-2 Inhibitors Reduce Steroid-Insensitive Airway Inflammation.

Bcl-2 Antagonist ABT-737 Attenuates Corticosteroid-Insensitive Neutrophilic Airway Inflammation

Blockade of NLRP3/Caspase-1/IL-1β Regulated Th17/Treg Immune Imbalance and Attenuated the Neutrophilic Airway Inflammation in an Ovalbumin-Induced Murine Model of Asthma